GlassScriptPhysician profile
Madilyn Gray Smith
NPI 1407307598
$3,323.62
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $795 · 2022: $1,209 · 2023: $906 · 2024: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,319.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $772.16 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $264.57 | 2021-2023 | Dificid, Verquvo, Zerbaxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.79 | 2021-2024 | Jardiance, Synjardy |
| Lilly USA, LLC | $192.35 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $144.22 | 2021-2022 | |
| Theratechnologies INC. | $141.23 | 2021-2024 | Egrifta, Trogarzo |
| Pfizer INC. | $123.93 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $114.14 | 2021-2022 | |
| Glaxosmithkline, LLC. | $112.87 | 2023-2024 | Trelegy Ellipta |
| Janssen Biotech, INC. | $111.10 | 2022-2023 | Symtuza |
| Janssen Pharmaceuticals, INC | $110.27 | 2021-2022 | |
| Viiv Healthcare Company | $108.40 | 2021-2024 | Cabenuva, Dovato |
| Abbvie INC. | $108.03 | 2021-2024 | |
| Mylan Specialty L.P. | $104.55 | 2021-2024 | Yupelri |
| Xeris Pharmaceuticals, INC. | $70.26 | 2022-2023 | Gvoke Hypopen |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $70.00 | 2022-2023 | Nuzyra |
| Amarin Pharma, INC. | $69.95 | 2021-2022 | |
| Gilead Sciences, INC. | $67.18 | 2021-2024 | Biktarvy |
| Daiichi Sankyo INC. | $63.84 | 2022-2023 | Injectafer |
| Exact Sciences Corporation | $54.29 | 2023 | Cologuard Collection Kit |
| Melinta Therapeutics, LLC | $46.71 | 2022 | |
| Novartis Pharmaceuticals Corporation | $35.48 | 2023 | |
| Shionogi INC | $32.91 | 2024 | Fetroja |
| Amgen INC. | $31.41 | 2023 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $31.23 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.43 | 2022 | |
| Supernus Pharmaceuticals, INC. | $28.38 | 2021 | |
| Dexcom, INC. | $19.10 | 2023 | Dexcom G6 Transmitter |
| Therapeuticsmd, INC. | $17.00 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.48 | 2021 | |
| Almatica Pharma LLC | $12.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madilyn Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.